Drug Database
MI

miriplatin hydrate (miriplatin hydrate / SMP 11355 / Miripla)

✓ Approved

Sumitomo Pharma Co., Ltd. · Small Molecule · Small Molecule

What is miriplatin hydrate?

miriplatin hydrate is a small molecule developed by Sumitomo Pharma Co., Ltd.. It is approved for therapeutic indications via injectable (others) or intraarterial injection.

Drug Profile

Brand Namesmiriplatin hydrate, SMP 11355, Miripla
CompanySumitomo Pharma Co., Ltd.
Drug ClassSmall Molecule
RouteInjectable (Others), Intraarterial Injection
StatusApproved
Sources: ClinicalTrials.gov, Sumitomo Pharma Co., Ltd.

Therapeutic Indications

miriplatin hydrate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatic cancer✓ Approved

Related Research Articles

PubMedScientific reports2026-05-30

Surface gas hydrates and seep features in the Krishna Godavari Basin, Bay of Bengal.

Raj V B Subin VBS, Lal M A Sarun MAS, Ramesh S S, Ramesh N R NR et al.

The Krishna-Godavari (K-G) Basin along the eastern continental margin of India is characterized by active methane seepage and documented subsurface gas hydrate accumulations; however, constraints on gas hydrate occurring at or near the seafloor remain limited. Here, we present high-resolution acoustic and visual observations from an autonomous underwater vehicle (AUV) documenting localized near-seafloor gas hydrate exposure within an asymmetric mound-pockmark complex at ~ 1750 m water depth. Co-registered multibeam bathymetry, High-resolution Interferometric Synthetic Aperture Sonar (HISAS) backscatter, sub-bottom profiles (SBP), RMS amplitude analysis, and optical imagery reveal a white crystalline layer (~ 0.65 m thick) exposed at the sediment-water interface beneath a thin carbonate-cemented crust. Elevated backscatter intensity and enhanced RMS amplitudes coincide with this exposure, while shallow acoustic blanking and fracture-like discontinuities indicate underlying gas-charged sediments and focused methane migration pathways. Phase stability analysis confirms that the present bottom-water pressure-temperature conditions support hydrate stability at or near the seafloor. The integrated observations are consistent with hydrate mound-pockmark system formed through episodic methane flux, shallow hydrate crystallization, localized uplift, partial sealing, and subsequent collapse. These results provide new constraints on near-seafloor gas hydrate occurrence in the K-G Basin and demonstrate the value of high-resolution AUV surveys for resolving small-scale, structurally controlled hydrate systems.

PMID 42215545
Read full article →
PubMedChemical communications (Cambridge, England)2026-05-28

A long-lived ruthenium(II) complex-based time-gated luminescent probe for background-free detection of hydrazine hydrate.

Liu Chaolong C, Shi Run R, Du Liping L, Wang Wenyu W et al.

A ruthenium(II) complex-based luminescent probe, Ru-COU, is developed for hydrazine hydrate detection. Ru-COU and its hydrazone product exhibit long luminescence lifetimes, enabling the probe to be used for TGL detection of hydrazine hydrate. The assay demonstrates high sensitivity, excellent selectivity, and successful application in drug, food, and water samples.

PMID 42205093
Read full article →
PubMedThe British journal of psychiatry : the journal of mental science2026-05-28

Drugs for anxiety: from chloral hydrate to novel therapeutics.

Haddad Peter M PM

Anxiety disorders are common and disabling. Current drugs have limited efficacy, notable side-effects and little innovation. This editorial briefly reviews past, current and emerging anxiolytic treatments, including psychedelic-assisted therapies, and highlights key themes. There remains a major need for improved medications to reduce disability and improve quality of life.

PMID 42204914
Read full article →
PubMedEnergy & fuels : an American Chemical Society journal2026-05-27

Consolidation and Permeability of the B1 and D1 Gas Hydrate Bearing Sands and Associated Seal Sediments of the Extended-Duration Gas Production Test Site on the Alaska North Slope.

Tepecik Imgenur I, Seol Yongkoo Y, Waite William F WF, Dai Sheng C SC

Gas hydrate, a solid combination of gas (mostly methane in nature) and water molecules stable at low temperatures and elevated pressures, occurs naturally in marine and permafrost-associated environments. Gas hydrate reservoirs, such as those in the Alaska North Slope, have been considered potential energy resources for gas production. To understand the petrophysical and geo-mechanical characteristics of the reservoir, core samples retrieved from the site of the JOGMEC-DOE-USGS collaborative gas hydrate R&D project have been analyzed in the laboratory for their hydraulic and mechanical properties. This paper focuses on both seal and reservoir samples associated with the B1 and D1 sands, which are evaluated for index properties (including porosity, grain size distribution, liquid and plastic limits, specific surface area, and specific gravity), consolidation, permeability, and water retention. Furthermore, the reservoir core samples were tested with pore-filling, laboratory-grown tetrahydrofuran hydrate, in order to assess reservoir behavior during gas production from hydrates. Under simulated in situ stress conditions, the seal and hydrate-free reservoir cores had a permeability anisotropy ratio of k h/k v = 3.0-5.0, and k h/k v = 2.4-3.0 for the reservoir tetrahydrofuran hydrate-bearing cores. The data suggest that depressurizing the reservoir to induce hydrate dissociation alters the reservoir effective permeability in three ways: permeabilities decrease due to porosity lost (e.g., the initial reservoir thickness can decrease by up to 5% upon 7 MPa depressurization), permeability increases due to the loss of solid hydrate in the pore space, and permeability anisotropy k h/k v decreases in response to the evolving pore-space geometry. We show that given the simulated in situ gas hydrate saturations (i.e., S h = 32% in core 7P-2E and S h = 21% in core 20P-4), gas production from the dissociation of tetrahydrofuran hydrate in the two tested cores results in a net increase in effective permeability and a decrease in k h/k v. This study highlights the importance of investigating seal and reservoir sediments and the impacts of depressurization on the porosity and permeability responses during production.

PMID 42200156
Read full article →
PubMedEnvironmental science & technology2026-05-27

Tunable Strategies for Controlled CO2 Hydrate Formation: Integrating Promoter-Driven Regulation and Cage Occupancy Analysis.

Peng Hao H, Zhang Ye Y, Xu Chenlu C, Ren Jinfeng J et al.

Hydrate-based carbon sequestration offers a promising pathway for offshore CCS by exploiting the complementary properties of structure I (sI) and structure II (sII) hydrates in different sedimentary domains. Here, we employed Diffuse Reflectance Infrared Fourier Transformations Spectroscopy (DRIFTS) and chemical potential calculations to quantify cage occupancies in binary 1,3-dioxane/CO2 hydrates. At 8.5 °C and 3.6 MPa with 5.56 mol % dioxane, the large (51264) and small (512) cage occupancies by CO2 were determined to be 0.0810 and 0.7696, respectively. A numerical program was developed to calculate gas uptake, hydration number, density, and hydrate molar mass by incorporating cage occupancies and CO2 solubility in saltwater. Stirring speed and gas-water ratio were optimized for hydrate formation in seamud, yielding an optimal stirring rate of 800 rpm and a gas-liquid ratio of 5. Kinetic experiments across 1,3-dioxane concentrations (5.56 and 2.86 mol %) and diverse kinetic promoters (SL-Na, l-Trp, l-Lys; 300-2000 ppm) reveal that 5.56 mol % 1,3-dioxane/CO2 hydrate achieves a t90 of 2.44 min and a gas uptake of 73.526 mmol/mol (millimoles of gas/mol of saltwater), while the optimal sI hydrate pathway was identified as 800 ppm of SL-Na, with a corresponding t90 and uptake of 18.78 min and 53.719 mmol/mol, respectively. These findings highlight the potential of integrating cage occupancy insights with promoter optimization to design stratified sealing strategies, advancing safe and efficient offshore CO2 sequestration.

PMID 42200788
Read full article →
PubMedNature and science of sleep2026-05-27

Chloral Hydrate in the Treatment of Severe Insomnia When Other Treatments Have Failed: Results From a Real-World Evidence Study (RESTORE).

Groeger John A JA, Twelves John Luke JL, Multmeier Jan J, Swayze Hannah H et al.

The efficacy and safety of chloral hydrate, used as approved for severe insomnia in the UK, were assessed in a single-arm, open-label, real-world, decentralized clinical trial using contemporary self-reported outcome measures. Participants (18-75 years) had clinically significant impairment by severe insomnia (Insomnia Severity Index (ISI) score of 20-28), and history of behavioral and pharmacological sleep therapy failure. Specialists confirmed the clinical diagnosis and prescribed chloral hydrate (500 mg/5 mL oral solution, 430 or 860 mg daily) for 2 weeks followed by a 4-week follow-up period. Endpoints included change in ISI score from confirmatory diagnosis to treatment end (primary); and sleep measures, health-related quality of life (HRQoL), anxiety, depression, and adverse events (AEs; secondaries). Of the 96 participants (mean baseline ISI, 24.03 [SD, 2.06]), 85 completed the study. Improvements were observed with ISI at treatment end (week 2 mean change was -10.79 [95% confidence interval, -12.12, -9.47]; n=93; week 6 mean change was -8.04 (95% confidence interval, -9.13, -6.95; p < 0.0001; n=85), exceeding the 6-point change considered a minimal clinically important difference. Self-reported sleep measures including Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index, HRQoL, and anxiety shows significant improvements during treatment with some outcomes indicating continued benefit up to 4 weeks post-treatment. Most treatment-related AEs were mild in nature (83.9%, 256/305 events) including wind (73.9%), headache (58.7%), and stomach pain (31.5%). While no events met criteria for serious or severe intensity, seven participants (7.6%) withdrew owing to AEs. Short-term UK-approved chloral hydrate may provide a potential option for severe adult insomnia only when prior treatments have failed. NCT06053840 (https://clinicaltrials.gov); ISRCTN10433315 (https://www.isrctn.com/).

PMID 42199304
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about miriplatin hydrate